COMMUNIQUÉS West-GlobeNewswire

Orion Group Interim Report January-September 2018

24/10/2018 - 11:01

ORION CORPORATION INTERIM REPORT JANUARY-SEPTEMBER 2018 24 OCTOBER 2018 at 12.00 EEST Orion Group Interim Report January-September 2018 Orion's net sales for continuing operations in January-September 2018 totalled EUR [...]

PCI Biotech: Capital increase registered and listing of new shares

24/10/2018 - 11:01

Oslo, Norway, 24 October 2018. Reference is made to the previous announcements by PCI Biotech Holding ASA ("PCI Biotech" or the "Company") in respect of the issuance of 170,000 new shares following exercise of employee [...]

EssilorLuxottica : Mise à disposition d'une note complémentaire au prospectus ayant reçu le visa n°18-460 de l'AMF le 28 septembre 2018

24/10/2018 - 08:01

Mise à disposition d'une note complémentaire au prospectus ayant reçu le visa n°18-460 de l'AMF le 28 septembre 2018 Version PDF du communiqué Charenton-le-Pont, France (24 octobre 2018 - 8h00) - EssilorLuxottica [...]

Rule 2.9 Announcement

24/10/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 24 October 2018 [...]

Interim report for the first nine months of 2018

24/10/2018 - 07:58

Read the full announcement in PDF Attachment 2018_60_Q32018_CompanyAnnouncement_EN_FINAL

Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met

24/10/2018 - 07:31

ORION CORPORATION STOCK EXCHANGE RELEASE 24 OCTOBER 2018 AT 8.30 a.m. EEST Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The [...]

Santhera Announces Start of Phase Ib/IIa Trial with POL6014 in Patients with Cystic Fibrosis

24/10/2018 - 07:01

Pratteln, Switzerland, October 24, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces the start of a Phase Ib/IIa multiple ascending dose (MAD) trial with POL6014 in patients with cystic fibrosis (CF). POL6014 is an [...]

ISS and Glass Lewis recommend ICC Shareholders vote FOR Arrangement with Aurora Cannabis

24/10/2018 - 03:58

VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- ICC Labs Inc. (the Company or ICC ) (TSX-V: ICC) is pleased to announce that Institutional Shareholder Services Inc. ( ISS ) and Glass Lewis & Co. ( [...]

Lexington Provides Q3 Corporate Review

24/10/2018 - 00:37

VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to review [...]

Psychemedics Announces Quarterly Results

23/10/2018 - 23:30

Declares 89 th Consecutive Quarterly Dividend ACTON, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2018 [...]

BioCryst to Report Third Quarter 2018 Financial Results on November 6

23/10/2018 - 22:15

RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will report its third quarter 2018 financial results on Tuesday, November 6, [...]

Cutera, Inc. to Announce Third Quarter 2018 Results

23/10/2018 - 22:05

BRISBANE, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq:CUTR) (“Cutera” or the “Company”), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, will announce [...]

SeaSpine to Report Third Quarter 2018 Financial Results on November 6, 2018

23/10/2018 - 22:05

CARLSBAD, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]

Sientra® to Release Third Quarter 2018 Financial Results on November 6, 2018

23/10/2018 - 22:05

SANTA BARBARA, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company (“Sientra or the “Company”), announced today that the Company will release its third quarter 2018 [...]

LogicBio Therapeutics Announces Closing of Initial Public Offering

23/10/2018 - 22:05

CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet [...]

Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results

23/10/2018 - 22:01

Updated Regulatory Strategy Based on 12-Week Flare-up Data from Completed Phase 2 Program and Consultation with the FDA NDA Submission Planned for the Second Half of 2019 MONTREAL, Oct. 23, 2018 (GLOBE NEWSWIRE) -- [...]

Clementia annonce son plan de soumettre une présentation de nouvelle drogue (New Drug Application) pour le palovarotène dans le traitement de la FOP à la suite de résultats positifs de la phase 2

23/10/2018 - 22:01

Mise à jour de la stratégie réglementaire en utilisant les données de poussées actualisées de la semaine 12 du programme de phase 2 et en consultation avec la FDA Soumission d’une NDA prévue pour le second semestre de [...]

Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

23/10/2018 - 22:01

Topline efficacy and safety results anticipated by early April 2019 MENLO PARK, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity [...]

Krystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option

23/10/2018 - 22:01

PITTSBURGH, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from [...]